Clinical Trials
5
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- Drug: D07001-Softgel CapsulesDrug: PlaceboCombination Product: Capecitabine
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT06622057
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: D07001-softgel capsules + Xeloda (or TS-1)Drug: mFOLFOX
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05065957
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳National Taiwan University Cancer Center, Taipei, Taiwan
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
- Conditions
- Gastrointestinal CancerBiliary Tract Cancer
- Interventions
- Drug: D07001-softgel capsules
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03531320
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng-Kung University Hospital, Tainan, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
- Conditions
- Advanced Solid MalignanciesMalignant Lymphomas
- Interventions
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01800630
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01678690
- Locations
- 🇺🇸
Georgia Regents University- Cancer Center, Augusta, Georgia, United States
🇺🇸Gabrail Cancer Center Research, Dover, Ohio, United States
🇨🇳National Taiwan University Hospital, Taipei, Taiwan